title: Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease.
abstract: Kawasaki disease is an autoimmune disease found predominantly in children under the age of 5 years. Its incidence is higher in those who live in Asian countries or are of Asian descent. Kawasaki disease is characterized as an acute inflammation of the vasculature bed affecting mainly the skin, eyes, lymph nodes, and mucosal layers. Although the disease is usually self-limiting, patients may develop cardiac abnormalities that can lead to death. The exact cause of the disease is unknown; however, researchers hypothesize that an infectious agent is responsible for causing Kawasaki disease. Initial treatment options with intravenous immune globulin and aspirin are sufficient to cure most patients who acquire this disease. Unfortunately, in up to one-quarter of patients, the disease will be refractory to initial therapy and will require further management with corticosteroid, immunomodulatory, or cytotoxic agents. The lack of randomized, controlled trials makes treatment of refractory disease difficult to manage. Until larger randomized, controlled trials are published to give more guidance on therapy for this stage of disease, clinicians should use the data available from observational studies and case reports in conjunction with their clinical expertise to make treatment decisions.
authors.affiliation: Department of Pharmacy, Moses H. Cone Hospital, Greensboro, North Carolina.
authors.forename: Seyyedeh
authors.initials: S
authors.lastname: Saneeymehri
authors.affiliation: Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
authors.forename: Katherine
authors.initials: K
authors.lastname: Baker
authors.affiliation: Department of Pharmacy, Moses H. Cone Hospital, Greensboro, North Carolina.
authors.forename: Tsz-Yin
authors.initials: TY
authors.lastname: So
keywords: autoimmune disease; cyclophosphamide; cyclosporin; infliximab; methotrexate; methylprednisolone; mucocutaneous lymph node syndrome